pufa 22:4

PUFA 22:4 refers to a specific polyunsaturated fatty acid with 22 carbon atoms and four double bonds, commonly known as adrenic acid (all‑cis‑7,10,13,16‑docosatetraenoic acid). It is an omega‑6 fatty acid that is synthesized in the body from arachidonic acid via elongation and is found in tissues such as the brain's white matter, adrenal glands, and cell membranes. It differs from more commonly discussed PUFAs like linoleic acid (18:2) and arachidonic acid (20:4) by its longer chain and distinct structure. Although most polyunsaturated fatty acids like omega‑3 (e.g., EPA, DHA) and omega‑6 linoleic acid are discussed in nutrition guidance, adrenic acid itself has not been assigned an official dietary recommendation by major nutrition authorities. Dietary intake of adrenic acid typically comes from animal foods where it is present in small amounts in fats and phospholipids. As a structural lipid, it contributes to the fluidity and function of neuronal and other cell membranes. Research indicates adrenic acid is metabolized by enzymes including cyclooxygenase, lipoxygenase, and cytochrome P450, forming bioactive lipid mediators. These metabolites may influence inflammation and vascular tone, although the physiological significance of dietary intake is not fully established. Because it is not essential (the human body can produce it from other fatty acids), it is not included in official nutrient intake lists or dietary reference intakes established by NIH or similar agencies.

Adrenic acid's primary recognized functions are structural and biochemical. It is a significant component of glycerophospholipids in brain white matter and cell membranes, contributing to membrane flexibility and signaling processes. In neural tissues, adrenic acid serves as one of the most plentiful long‑chain PUFAs alongside docosahexaenoic acid (DHA) and arachidonic acid. This distribution suggests it plays a role in nervous system development and function. While adrenic acid itself is not classified as an essential nutrient, its metabolic derivatives participate in complex signaling pathways. Enzymatic metabolism via cytochrome P450 yields epoxydocosatrienoic acids (EDTs) and dihydroxydocosatrienoic acids (DHDTs), which have been studied for potential anti‑inflammatory and vasodilatory effects. Some preclinical studies suggest these metabolites may affect processes such as analgesia and reduction of stress in endoplasmic reticulum models, though human clinical data remain limited. In addition, adrenic acid contributes to the pool of very‑long‑chain PUFAs that serve as precursors to eicosanoids and similar signaling lipids, which regulate inflammation and vascular tone. However, unlike the more extensively studied omega‑3 fatty acids (EPA, DHA) known for cardiovascular benefits including lowering triglycerides and reducing arrhythmia risk, adrenic acid's direct health benefits from dietary intake are not well documented. Most evidence for health effects is derived from biochemical and cell‑based research, with human intervention studies sparse. As a constituent of phospholipids, maintaining balanced intake of diverse PUFAs, including adrenic acid, within a dietary pattern rich in essential fatty acids may indirectly support overall fatty acid balance and cell membrane function.

There are no established dietary reference intakes, recommended dietary allowances (RDAs), or adequate intakes (AIs) specifically for adrenic acid. Unlike essential fatty acids such as linoleic acid and alpha‑linolenic acid that have defined intake recommendations, adrenic acid is a non‑essential PUFA synthesized endogenously from arachidonic acid and typically present at low concentrations in foods. Therefore, formal guidance on intake levels by age, sex, or life stage is not provided by the NIH Office of Dietary Supplements or other major nutrition authorities. Because of this, quantifying a specific daily requirement is not possible, and adrenic acid is generally considered in the context of total PUFA consumption rather than as a standalone nutrient. Total polyunsaturated fat intake recommendations primarily focus on replacing saturated fats with PUFAs to support cardiovascular health. For example, dietary guidelines often suggest that polyunsaturated and monounsaturated fats replace saturated fats to improve lipid profiles. While adrenic acid contributes a small portion of total PUFA intake, the emphasis remains on consuming foods rich in essential PUFAs—omega‑3 and omega‑6 fatty acids—with established health benefits. Given this context, ensuring a diet with balanced PUFA sources, including essential fatty acids, provides substrates for endogenous synthesis of longer chain PUFAs like adrenic acid. There is no evidence that focusing on adrenic acid intake specifically yields direct health benefits beyond general fatty acid balance within recommended dietary patterns.

Because adrenic acid is a non‑essential fatty acid that the body can synthesize from arachidonic acid, there are no defined deficiency syndromes attributable solely to inadequate intake of adrenic acid itself. Traditional deficiency symptoms associated with fatty acids relate to essential fatty acids (EFA). For example, linoleic acid (an omega‑6) deficiency can lead to scaling dermatitis, poor wound healing, and growth retardation in children, while alpha‑linolenic acid deficiency affects neural development and inflammatory balance. However, adrenic acid participates in cellular lipid pools that support membrane structure and signaling pathways. If total PUFA status is poor, cellular membrane composition may be altered, potentially affecting neural tissue function or inflammatory mediator synthesis. Because studies specifically examining isolated adrenic acid deficiency are lacking, specific clinical signs cannot be attributed to low dietary adrenic acid. In practice, inadequate intake of broader PUFA subclasses such as omega‑3 and omega‑6 is more clinically relevant. Laboratory assessment of fatty acid profiles may reveal altered proportions of long‑chain PUFAs, including adrenic acid, but interpretation requires expert clinical context, and standardized reference ranges for adrenic acid are not widely established. At‑risk populations for PUFA imbalance include individuals with very low fat intake, malabsorption syndromes, or genetic disorders affecting fatty acid metabolism. However, these conditions influence overall fatty acid status rather than isolated deficiency of this 22:4 PUFA. Thus, specific deficiency symptoms for adrenic acid are not recognized in clinical nutrition literature.

Adrenic acid is found in animal‑derived foods, typically in the fat component and phospholipids of tissues. Foods with measurable adrenic acid include meats and animal fats, particularly poultry, pork products, and certain marine oils with documented 22:4 content. For example, bearded seal oil and beluga oil are among the highest sources of adrenic acid, though such traditional foods are regionally specific. Common foods with adrenic acid include turkey breast, pork sausage, bacon, and cured meats, with ground cloves also contributing trace amounts. Processed meats such as salami, pepperoni, and frankfurters contain low milligram amounts per 100‑gram serving. Because adrenic acid is a minor PUFA component in most foods, total PUFA intake from diverse sources—nuts, seeds, vegetable oils, and fatty fish rich in other PUFAs—contributes more substantially to overall polyunsaturated fat status. Nevertheless, incorporating a variety of animal and plant sources of PUFAs supports a broad fatty acid profile. Culinary herbs and spices can also contain trace long‑chain PUFAs, including adrenic acid, but their nutritional contribution is minor relative to meats and oils. When selecting foods for dietary PUFA intake, focus remains on foods rich in essential PUFAs like omega‑3 EPA and DHA from fatty fish, and omega‑6 linoleic acid from plant oils, which have extensive evidence for health benefits. The foods listed in the food sources table reflect specific adrenic acid content where data are available.

Like other dietary fatty acids, adrenic acid is absorbed in the small intestine following digestion of triglycerides and phospholipids. Dietary fats are emulsified by bile acids and incorporated into micelles, facilitating uptake by enterocytes. Within enterocytes, PUFAs including adrenic acid are re‑esterified into triglycerides and phospholipids and packaged into chylomicrons for transport via the lymphatic system. Because adrenic acid typically comprises a small fraction of total dietary fat, its absorption parallels that of other long‑chain fatty acids and depends on effective fat digestion and pancreatic enzyme function. Conditions impairing fat absorption, such as pancreatic insufficiency, celiac disease, or cholestatic liver disease, can reduce absorption of PUFAs. Bioavailability may also be influenced by the food matrix; fats consumed within whole foods are absorbed differently than isolated fatty acids. Presence of other dietary components like fiber may modestly impact fat absorption kinetics. Once absorbed, adrenic acid is incorporated into tissue phospholipids, particularly in the brain and adrenal glands, reflecting its structural role. Factors that enhance absorption of PUFAs include co‑consumption of dietary fat (stimulating bile acid release) and normal gastrointestinal function. Conversely, inhibitors of fat digestion or absorption will reduce PUFA uptake generally rather than specifically affecting adrenic acid.

Adrenic acid supplements are not commonly available and are not recommended for general use. Because adrenic acid is a non‑essential fatty acid that the body can synthesize from arachidonic acid, supplementation is not necessary for most people. No authoritative health organization endorses adrenic acid supplementation for health outcomes. Research on potential supplementation focuses on biochemical pathways and experimental models rather than clinical efficacy. Some niche studies suggest that adrenic acid metabolites may participate in anti‑inflammatory pathways, but these findings have not translated into established therapeutic recommendations. In contrast, supplementation with essential PUFAs like omega‑3 EPA and DHA has well‑documented benefits for cardiovascular and cognitive health. Therefore, if the goal is to support overall PUFA status, emphasis should be on dietary sources of essential PUFAs rather than isolated adrenic acid supplements. Individuals with specific health conditions involving fatty acid metabolism should consult healthcare professionals before considering any fatty acid supplementation. Overall, routine supplements containing adrenic acid are neither widely studied nor broadly recommended.

No tolerable upper intake levels have been established for adrenic acid, and there is no evidence indicating toxicity from typical dietary intake. As a minor PUFA component in foods, adrenic acid contributes a small proportion of total fat intake. High total fat intake, including PUFAs, may contribute to excessive caloric consumption and weight gain if energy balance is not maintained. However, isolated toxicity or adverse effects attributable solely to adrenic acid have not been described. Standard dietary recommendations focus on replacing saturated fats and trans fats with polyunsaturated and monounsaturated fats to support cardiovascular health. Erring toward balanced PUFA intake rather than excessive consumption of any single fatty acid is prudent.

There are no well‑documented direct drug interactions specific to adrenic acid supplementation because it is not used clinically as a supplement. However, fatty acid metabolism in general can interact with medications that affect lipid absorption or metabolism. For example, medications like orlistat, which inhibit fat absorption, may reduce uptake of dietary PUFAs. Additionally, drugs influencing cytochrome P450 enzyme activity could theoretically influence metabolism of PUFAs and their derivatives, although direct clinical interactions involving adrenic acid are not established. Patients taking lipid‑modifying therapies should discuss fatty acid intake with clinicians.

Common Forms: none standard

Typical Doses: not established

When to Take: not applicable

Best Form: not applicable

⚠️ Interactions: No specific interactions documented